NVAX stock news · Novavax Inc.
Get alerts for NVAX
Follow Novavax Inc. (NVAX) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for NVAXNovavax's second-biggest investor sold $32.6 million worth of stock and stopped pushing for changes.
NeutralShah Capital sold about 2.9 million Novavax shares and ended its campaign, but kept 6.46%. Mixed vaccine news means this does not change Novavax's outlook.
Stephen King criticizes Trump’s new press secretary for her old posts about vaccines and election claims.
NeutralThe story mentions Novavax’s recent share rise but reports no new company development or link between the dispute and Novavax’s business.
Novavax shared details from its call about money made in the second quarter of 2026.
Good for NVAXNovavax reported progress with Sanofi and other partners that could bring payments and wider use of its vaccine technology. The update is favorable, but those payments depend on future steps.
Novavax shares drop after a big jump yesterday. What happened?
NeutralNovavax shares pulled back after rising on reports of a suspected plague case in Russia. No new company result or vaccine sale is reported, so the story does not change its outlook.
Moderna, Vaxcyte, and Novavax are getting attention after a possible pneumonic plague case in Russia worries people.
NeutralNovavax was named among vaccine stocks, but the report gives no company-specific product or trial update. The suspected Russia case alone does not show a change to its business outlook.
People betting against Novavax are worried as fears of a plague in Russia grow.
NeutralNovavax rose on fears of a possible plague outbreak, but plague is unconfirmed and bacterial. The story reports no new sales, so its business outlook is unchanged.
Big trades in 10 health care stocks happened today.
NeutralNovavax had a call trade labeled neutral. The report gives no company news, so it does not change the company's outlook.
Wednesday sees an uptick in Novavax shares: What factors are fueling this surge?
NeutralNovavax's stock is experiencing a significant increase following a landmark clinical trial result from Merck and Moderna, which has sparked a rally across the biotechnology sector. This positive momentum is expected to enhance investor sentiment towards Novavax, particularly as it continues to leverage its proprietary adjuvant platform in the evolving landscape of cancer therapies.